Biomedical Engineering Seminar - 28 April 2015
Apr 28, 2015
from 12:45 PM to 01:45 PM
|Where||Ludwig/Jenner Seminar Room, Rm 678.00.59A, Old Road Campus Research Building, Headington, Oxford|
|Contact Name||Professors Robin Cleveland and Eleanor Stride|
|Contact Phone||+44(0)1865 617737/617747|
|Add event to calendar||
Profound discoveries in physics lie at the heart of biomedical imaging, which has revolutionised diagnostic medicine in the last 30 years. Our research programme aims to develop and translate new technologies that exploit a region of the electromagnetic spectrum that remains relatively under-used for this purpose, namely the visible and near-infrared range. I will introduce the importance of this spectral range for revealing the role of oxygen consumption and oxidative stress in cancer progression. I will then present some of our efforts to access the contrast available in this range in vivo, going directly to the site of interest with new endoscopy methods or enhancing depth of penetration using hybrid techniques, such as optoacoustic imaging. In each case, I will outline the potential of the approach for addressing an unmet need in cancer imaging as well as the challenges for clinical translation.
Dr Sarah Bohndiek completed her PhD in Physics at University College London in 2008 and then worked in both the UK and USA at Stanford University as a postdoctoral fellow in molecular imaging. During that time, Sarah published over 30 research articles on molecular imaging of cancer, which have received over 700 citations. She was awarded the Institute of Physics Paterson Medal, WISE Research Award and MSCA Prize in 2014 recognition of this work.
Sarah is now a group leader jointly appointed in the Department of Physics and the Cancer Research UK Cambridge Institute at the University of Cambridge, UK. She leads an international research team whose focus is the development of new techniques for imaging oxygen and oxidative stress in cancer. In particular, their goal is to translate new approaches in optical molecular imaging into the clinic, to gain a better understanding of cancer drug resistance.